Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc
with an Outperform rating and a price target of $40.
The analysts Leland Gershell and Rohan Mathur note significant room for improvement in drugs targeting various chronic endocrine disorders. Current options either have suboptimal benefit/risk profiles, problematic administration routes, or inadequate frequency.
The well-understood biology of peptide hormone signaling through G protein-coupled receptors makes them the therapeutic targets of choice, and Crinetics Pharmaceuticals is distinguished by its ability to create oral, once-daily non-peptide drug candidates to endocrine GPCRs
Oppenheimer writes that Crinetics Pharmaceuticals is well-positioned to meaningfully improve the treatment condition for a growing number of chronic endocrine disorders through its non-peptide drug discovery capability against well-understood targets.
Phase 3 development success in acromegaly could pave the way for oral paltusotine to generate ~$250 million in peak sales, and next quarter's Phase 2 look in neuroendocrine tumors could bring ~2x that initial opportunity into focus.
The analysts hold a positive outlook for the forthcoming Phase 2 outcomes of the daily oral ACTH antagonist CRN04894, anticipating it will establish proof-of-concept for both Cushing's syndrome and Congenital adrenal hyperplasia. Additionally, CRNX is progressing towards addressing more common medical conditions, as its early-stage initiatives for Graves' disease/Thyroid eye disease and diabetes/obesity are advancing toward clinical trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.